Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Sorafenib (Primary) ; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 08 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History